![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
PHARMACEUTICAL MARKETING INVESTIGATION OF ANTI-ANGINAL DRUGS IN AMROHA
Khursheed Ali* and Mohd. Junaid
ABSTRACT A number of therapies are available for the treatment of angina, including: beta-blockers, calcium channel blockers, nitrates and a number of miscellaneous vasodilationagents. Four nitrates are currently available for use in the United States: amyl nitrite, isosorbide dinitrate, isosorbide mononitrate and nitroglycerin. Ranolazine is a newer agent with a unique mechanism of action which may also be used in the treatment and prevention of chronic angina. Sublingual nitroglycerin is used to treat an angina attack and the long-acting nitrates (transdermal and extended release nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) are used for prophylaxis of angina. Ischemic heart disease is one of the most frequently reported cardiovascular diseases in the US and angina pectoris is the most common symptom of ischemic heart disease. ACCF/AHA Guidelines for patients with Stable Ischemic Heart Disease recommend beta-blockers with or without short-acting sublingual nitroglycerin as first-line treatment. The long-acting nitrates and ranolazine may be considered second-line or add-on options in patients who are not able to tolerate beta-blockers or who require additional therapy to control angina. The nitrates and ranolazine may also be used in the treatment of unstable angina and angina associated with heart failure or myocardial infarction. Keywords: . [Download Article] [Download Certifiate] |